undamentalytics Newsletter
Sign in

Crispr Therapeutics AG cash flow statement

In fiscal 2025, Crispr Therapeutics AG's operations generated −$345m of cash; it spent $914,000 on capital projects, leaving free cash flow of −$346m.

Cash flow statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2015Dec 20152016Dec 20162017Dec 20172018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMSept 2026
Cash from operations59−53−70−9657−238539−496−260−143−345−375
Depreciation and amortisation013459182420191918
Stock-based pay411193544661029881877270
Capital spending138371882379212
Free cash flow58−56−78−9950−257457−533−270−145−346−377
Free cash flow after stock pay55−67−97−1346−323355−631−351−231−418−446
Share buybacks———0————————
Shares issued—890307415982213133301398111

Free cash flow is cash from operations minus capital spending. Free cash flow after stock pay also subtracts stock-based compensation, a real cost to shareholders that the cash flow statement adds back. Dividends, buybacks and shares issued are cash amounts for the period.

Compare with peers

Head to head: ABEO vs CRSPCRSP vs JANXCRSP vs STOK

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Crispr Therapeutics AG's SEC filings (10-K and 10-Q), retrieved November 3, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Crispr Therapeutics AG.